antibody

MDM2 (Ab-166) Antibody

MBS857043

0.05 mg

180 USD

polyclonal

rabbit

nonconjugated

immunohistochemistry, immunocytochemistry

Antibody

MDM2 (Ab-166) Antibody

MDM2

E3 ubiquitin-protein ligase Mdm2 isoform h; E3 ubiquitin-protein ligase Mdm2; E3 ubiquitin-protein ligase Mdm2; oncoprotein Mdm2; MDM2 oncogene, E3 ubiquitin protein ligase; Mdm2, p53 E3 ubiquitin protein ligase homolog; double minute 2, human homolog of; p53-binding protein; Mdm2, transformed 3T3 cell double minute 2, p53 binding protein; MDM2 proto-oncogene, E3 ubiquitin protein ligase; Double minute 2 protein; Hdm2; Oncoprotein Mdm2; p53-binding protein Mdm2

MDM2

MDM2; MDM2; HDMX; hdm2; ACTFS; Hdm2

MDM2_HUMAN

Polyclonal

IgG

Rabbit

Human

442

MDM2 (Ab-166) Antibody detects endogenous levels of total MDM2 protein.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

50ug/50ul

Store at -20 degree C for 1 year

Immunohistochemistry (IHC), Immunofluorescence (IF)

IHC: 1:50~1:100

Immunogen: The antiserum was produced against synthesized non-phosphopeptide derived from human MDM2 around the phosphorylation site of Serine 166 (A-I-SP-E-T). Pathway: DNA damage/repair

Cancer; Cardiovascular; Cell Biology; Epigenetics & Nuclear Signaling; Developmental Biologys; Immunology; Drug Discovery Products; Metabolism; Neuroscience; Signal Transduction; Stem Cells; Autophagy antibody

Haupt, Y. et al. (1997) Nature 387, 296-299. Zhou, B. P. et al. (2001) Nat. Cell Biol. 3, 973-981. Grossman, S. R. et al. (1998) Mol. Cell 2, 405-415. Mayo, L.D. and Donner, D.B. (2001) Proc. Natl. Acad. Sci. USA 98, 11598-11603.

223890205

NP_001138811.1

NM_001145339.2

Q00987

55,991 Da

AKT Phosphorylates Targets In The Cytosol Pathway (106475); Adaptive Immune System Pathway (366160); Androgen Receptor Signaling Pathway (198806); Apoptosis Pathway (198797); Aurora A Signaling Pathway (137925); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Cell Cycle Pathway (530733); Cell Cycle Checkpoints Pathway (105739); Cell Cycle Pathway (198811)

This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells. [provided by RefSeq, Jun 2013]

MDM2: a ubiquitin ligase for p53, plays a central role in regulation of the stability of p53 via Akt-mediated MDM2 phosphorylation. Phosphorylation of MDM2 increases its interaction with p300, providing a platform to allow the assembly of the protein complex necessary for MDM2-mediated ubiquitination and degradation of p53. Phosphorylation of MDM2 also blocks its binding to p19ARF, increasing the degradation of p53. Facilitates the nuclear export of p53 and targets it for proteasome-mediated proteolysis. Eight alternatively spliced isoforms have been reported. Protein type: Ligase; Inhibitor; Nucleolus; EC 6.3.2.19; Ubiquitin ligase; Ubiquitin conjugating system; Oncoprotein; EC 6.3.2.-. Chromosomal Location of Human Ortholog: 12q14.3-q15. Cellular Component: nucleoplasm; nuclear body; protein complex; cytoplasm; plasma membrane; nucleolus; synapse; cytosol; nucleus. Molecular Function: identical protein binding; protein binding; peroxisome proliferator activated receptor binding; enzyme binding; zinc ion binding; p53 binding; ubiquitin protein ligase binding; ubiquitin-protein ligase activity; ligase activity. Biological Process: viral reproduction; nerve growth factor receptor signaling pathway; protein ubiquitination during ubiquitin-dependent protein catabolic process; response to morphine; protein ubiquitination; negative regulation of caspase activity; negative regulation of transcription from RNA polymerase II promoter; positive regulation of mitotic cell cycle; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; response to carbohydrate stimulus; response to antibiotic; positive regulation of protein export from nucleus; synaptic transmission; negative regulation of DNA damage response, signal transduction by p53 class mediator; response to magnesium ion; establishment of protein localization; peptidyl-lysine modification; positive regulation of cell proliferation; protein complex assembly; response to iron ion; response to drug; epidermal growth factor receptor signaling pathway; traversing start control point of mitotic cell cycle; phosphoinositide-mediated signaling; fibroblast growth factor receptor signaling pathway; protein destabilization; response to ether; response to cocaine; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; innate immune response; regulation of protein catabolic process; negative regulation of transcription, DNA-dependent. Disease: Accelerated Tumor Formation, Susceptibility To

0.05 mg

180 USD

0.1 mg

215